ArticleAnnals of nuclear medicine2026
Diagnostic value of ⁶⁸Ga-DOTATATE PET/CT volumetric parameters in differentiating adrenal lesions.
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correlation ofDiagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAdrenal lesions encompass a wide spectrum ranging from benign, non-functional adenomas to potentially metastatic tumors such as pheochromocytoma (PHEO). In addition to clinical and biochemical evaluation, imaging plays a pivotal role in their characterization. This study aimed to investigate the diagnostic contribution of quantitative parameters obtained from ⁶⁸Ga-DOTATATE PET/CT (DOTA PET) in the differential diagnosis of adrenal lesions.
methodsPatients who underwent DOTA PET between 2013 and 2025 for adrenal lesion characterization, as well as those with incidentally detected adrenal lesions on DOTA PET performed for other indications, were retrospectively analyzed. Patients without adrenal pathology on DOTA PET constituted the control group. The final diagnoses was established using histopathology or radiological imaging. Quantitative parameters, including SUVmax of the lesion, liver, and normal adrenal gland, as well as volumetric indices —somatostatin receptor expressing tumor volume (SSTR-TV) and total lesion somatostatin receptor expression (SSTR-TL)— were calculated to assess lesion volume and receptor density.
resultsPHEO demonstrated significantly higher SUVmax and volumetric parameters compared with adrenal adenomas and normal adrenal glands (p < 0.05). ROC analysis yielded a sensitivity of 77% and specificity of 80% for SUVmax, using a threshold of 13. Volumetric parameters showed superior diagnostic accuracy: median SSTR-TV2.5 was markedly greater in PHEO than adenoma, and a threshold of 3.8 provided 94% sensitivity and 95% specificity (AUC = 0.97, p < 0.05). DeLong analysis confirmed that SSTR-TV2.5 outperformed SUVmax and lesion size (p < 0.05).
conclusionVolumetric parameters derived from DOTA PET, particularly SSTR-TV, provided high diagnostic accuracy in differentiating PHEOs from adrenal adenomas. These results indicate that quantitative assessment can serve as a valuable, non-invasive approach in characterizing adrenal lesions.
Indexed as
Identifiers
41774422What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.